RAPT Therapeutics, Inc.

NasdaqGM:RAPT Stock Report

Market Cap: US$153.9m

RAPT Therapeutics Management

Management criteria checks 2/4

RAPT Therapeutics' CEO is Brian Wong, appointed in Aug 2015, has a tenure of 9.5 years. total yearly compensation is $6.59M, comprised of 9.2% salary and 90.8% bonuses, including company stock and options. directly owns 0.37% of the company’s shares, worth $561.59K. The average tenure of the management team and the board of directors is 4.9 years and 7.3 years respectively.

Key information

Brian Wong

Chief executive officer

US$6.6m

Total compensation

CEO salary percentage9.2%
CEO tenure9.5yrs
CEO ownership0.4%
Management average tenure4.9yrs
Board average tenure7.3yrs

Recent management updates

Recent updates

Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

Nov 10
Can RAPT Therapeutics (NASDAQ:RAPT) Afford To Invest In Growth?

RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus

Jul 24

Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

Jun 13
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Could Be Quite Risky

RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

May 20

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

Feb 21
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

Sep 12
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

May 10
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Afford To Drive Business Growth

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Feb 07
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

Oct 12
We're Hopeful That RAPT Therapeutics (NASDAQ:RAPT) Will Use Its Cash Wisely

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jan 25
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Oct 15
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

RAPT Therapeutics (RAPT) skyrockets 100% on positive RPT193 data in early-stage atopic dermatitis study

Jun 14

RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Jun 08
RAPT Therapeutics (NASDAQ:RAPT) Is In A Good Position To Deliver On Growth Plans

Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

Mar 15
Should You Take Comfort From Insider Transactions At RAPT Therapeutics, Inc. (NASDAQ:RAPT)?

We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

Feb 15
We Think RAPT Therapeutics (NASDAQ:RAPT) Can Easily Afford To Drive Business Growth

RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

Jan 18
RAPT Therapeutics' (NASDAQ:RAPT) Stock Price Has Reduced 56% In The Past Year

CEO Compensation Analysis

How has Brian Wong's remuneration changed compared to RAPT Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$107m

Jun 30 2024n/an/a

-US$120m

Mar 31 2024n/an/a

-US$118m

Dec 31 2023US$7mUS$605k

-US$117m

Sep 30 2023n/an/a

-US$109m

Jun 30 2023n/an/a

-US$99m

Mar 31 2023n/an/a

-US$93m

Dec 31 2022US$5mUS$580k

-US$84m

Sep 30 2022n/an/a

-US$79m

Jun 30 2022n/an/a

-US$76m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$540k

-US$69m

Sep 30 2021n/an/a

-US$64m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$56m

Dec 31 2020US$4mUS$500k

-US$53m

Sep 30 2020n/an/a

-US$53m

Jun 30 2020n/an/a

-US$49m

Mar 31 2020n/an/a

-US$47m

Dec 31 2019US$2mUS$447k

-US$43m

Sep 30 2019n/an/a

-US$39m

Jun 30 2019n/an/a

-US$40m

Mar 31 2019n/an/a

-US$37m

Dec 31 2018US$1mUS$425k

-US$36m

Compensation vs Market: Brian's total compensation ($USD6.59M) is above average for companies of similar size in the US market ($USD1.39M).

Compensation vs Earnings: Brian's compensation has increased whilst the company is unprofitable.

CEO

Brian Wong (52 yo)

9.5yrs

Tenure

US$6,591,617

Compensation

Dr. Brian Russell Wong, M.D., Ph.D. serves as Venture Partner at The Column Group, LLC since joining the firm in 2022. He has been Chief Executive Officer and Director at RAPT Therapeutics, Inc. since Augu...

Leadership Team

NamePositionTenureCompensationOwnership
Brian Wong
CEO, President & Director9.5yrsUS$6.59m0.37%
$ 561.6k
Rodney K. Young
CFO, Principal Accounting Officer & Secretary5.2yrsUS$2.18m0.0087%
$ 13.4k
William Ho
Chief Medical Officer9.8yrsUS$1.90m0.012%
$ 17.9k
Steve Young
Vice President of Technologyno datano datano data
Dirk Brockstedt
Chief Scientific Officer5.7yrsUS$1.48m0.019%
$ 29.4k
Michael Listgarten
General Counsel2.1yrsno datano data
Gwen Carscadden
Chief Human Resources Officer2.8yrsno datano data
Paul Kassner
Senior Vice President of Biology4.9yrsno datano data
Jennifer Nicholson
Senior Vice President of Regulatory Affairs & Quality Assurance2.4yrsno datano data
Nipun Davar
Senior Vice President of Technical Operations1yrno datano data

4.9yrs

Average Tenure

57yo

Average Age

Experienced Management: RAPT's management team is considered experienced (4.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Brian Wong
CEO, President & Director9.5yrsUS$6.59m0.37%
$ 561.6k
Wendye Robbins
Independent Director5.4yrsUS$265.28k0.020%
$ 31.4k
Mary Gray
Independent Director5.2yrsUS$277.78k0%
$ 0
Andrew Pardoll
Member of Scientific Advisory Board7.8yrsno datano data
Philip Greenberg
Member of Scientific Advisory Board7.8yrsno datano data
Alexander Rudensky
Chairman of Scientific Advisory Boardno datano datano data
Scott Antonia
Member of Scientific Advisory Board7.4yrsno datano data
Emma Guttman-Yassky
Member of Scientific Advisory Board5.6yrsno datano data
Michael Giordano
Independent Director7.1yrsUS$267.78k0%
$ 0
Linda Kozick
Independent Director8.2yrsUS$260.78k0%
$ 0
Lori Lyons-Williams
Independent Chairman of the Board3.3yrsUS$262.28k0%
$ 0
Robert Zamboni
Member of Scientific Advisory Boardno datano datano data

7.3yrs

Average Tenure

64.5yo

Average Age

Experienced Board: RAPT's board of directors are considered experienced (7.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 19:44
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RAPT Therapeutics, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leon WangBarclays
Gao Yi ChenBerenberg
Guyn KimBMO Capital Markets Equity Research